You just read:

ContraVir Expands Phase 2a Trial of Tenofovir Exalidex (Formerly CMX157) to Include Doses above 100 mg

News provided by

ContraVir Pharmaceuticals, Inc.

19 Dec, 2016, 06:00 ET